Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tart cherry juice tested to stop Post-Surgery heart flutter

NCT ID NCT03793465

Disease control Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether drinking tart cherry concentrate for three days before heart valve surgery can reduce the risk of post-operative atrial fibrillation (an irregular heartbeat). The study involves 50 adults aged 50-79 who are in normal heart rhythm before surgery. Researchers will also measure inflammation-related gene activity in heart tissue to understand how the supplement might work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tart cherry concentrate
What this could lead to
If it works, this could point toward a simple dietary supplement to help prevent heart rhythm problems after cardiac surgery.
What could go wrong
This is a very small early-phase pilot study, so results may not be conclusive. The supplement may cause digestive discomfort and might not reduce atrial fibrillation at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2019

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and female patients (age 50-79) at the Mitral Valve Clinic/CVC undergoing elective cardiac surgery for mitral valve repair without the Cox MAZE procedure (MVR patients also undergoing CABG and/or tricuspid valve repair are also eligible) 2. In sinus rhythm (no pre-operative atrial fibrillation, no hx of AF) Exclusion Criteria: 1. Age ≥ 80 years 2. Diagnosed pre-operative chronic or paroxysmal AF 3. Prior ablation procedure for AF 4. Previous cardiac surgery 5. Implanted pacemaker 6. Active smoker 7. Comorbidities such as congenital or cardiac re-operation 8. Use of antiarrhythmic agents 9. Active inflammatory or infectious disease or malignancy 10. Diagnosed autoimmune disease 11. Corticosteroid or other immunomodulatory or immunosuppressive medication 12. Known sensitivity to sorbitol 13. Known gastric sensitivity to acidic juices like orange juice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitral valve disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mitral valve disorder atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-operative atrial fibrillation poaf

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.